In a recent study, researchers from the University of Illinois Urbana-Champaign in the United States have discovered that CAR-T cell immunotherapy could potentially be a highly effective treatment for solid tumors ifRead More…
In a recent study conducted by researchers from institutions including the MD Anderson Cancer Center at the University of Texas, USA, it has been discovered that the loss of metabolic capacity inRead More…
Immunotherapy strategies aim to utilize the patient’s own immune system cells to eliminate tumor cells. CAR-T cell therapy is an effective treatment for human blood cancers. In France, approximately 35,000 people areRead More…
A small-scale clinical trial suggests that an improved form of CAR-T cell therapy, known as Descartes-08, holds promise for treating myasthenia gravis, an autoimmune neuromuscular disease. The modified CAR-T therapy used inRead More…
Diffuse Intrinsic Pontine Glioma (DIPG) is an aggressive brain tumor that usually occurs in children between 5 and 7. This fast-growing tumor forms in the part of a child’s brain responsible forRead More…
In a recent study, researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), the Weizmann Institute of Science in Israel, the University of South Florida, and the University of Texas MDRead More…
Since the world’s first chimeric antigen receptor (CAR)-T cell therapy was approved for marketing in 2017, the Food and Drug Administration (FDA) has approved a total of six CAR-T cell therapies toRead More…
The success of CAR T cells in treating hematologic malignancies has provided impetus for the development of CAR T therapies in solid tumors. The biggest obstacle to the development of CAR TRead More…
Since 2017, when chimeric antigen receptor-T cells (CAR-T) were approved by the US Food and Drug Administration (FDA) as the first modified cell for the treatment of leukemia, five similar products haveRead More…
Chimeric antigen receptor (CAR) T cells have been remarkably successful in the treatment of relapsed hematologic malignancies, such as acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), and multiple myeloma (MM). CD19 andRead More…